Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Collaborative Neuroscience

Neither a doctor nor a teaching hospital

Research payments

$1,541,150

210 payments

Through program year 2024, Collaborative Neuroscience is reported as receiving $1,541,150 in research payments, across 210 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $8,089 1
2023 Research $224,371 10
2022 Research $266,443 9
2021 Research $420,249 61
2020 Research $506,508 95
2019 Research $115,490 34

Breakdown

Who paid Research payments · program years 2019–2024
  1. Allergan Inc. $965,109 158 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $232,449 10 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $208,872 2 payments
  4. Hoffmann-La Roche Limited $87,049 12 payments
  5. Adamas Pharmaceuticals, Inc. $39,584 26 payments
  6. Celgene Corporation $8,075 1 payment
  7. Eli Lilly and Company $12 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in Theprevention of Relapse in Patients With Schizophrenia $269,722 27 payments
  2. An Open Label, Prospective Study Assessing Positive Detection Accuracy and Detection Latency Measures of the Miniature Ingestible Event Marker Tablet Using the D-Tect Patch in Healthy Subjects and Assessing Detection Latency Measures Using the D-Tect Patch in Subjects With Serious Mental Illness Taking Abilify Mycite Tablet $232,449 10 payments
  3. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in Theprevention of Relapse in Patients With Schizophrenia $183,125 28 payments
  4. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $181,703 29 payments
  5. Connex 2 $145,157 1 payment
  6. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $129,566 29 payments
  7. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $126,084 24 payments
  8. Taar1 4 for Negative Symptoms $75,940 11 payments
  9. Proof of concept and DRF in MDD $63,715 1 payment
  10. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $39,813 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record